Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.

Anat AchironMathilda MandelSapir Dreyer-AlsterGil HarariDavid MagalashviliPolina SonisMark DolevShay MenascuShlomo FlechterRina FalbMichael Gurevich

Published in: Therapeutic advances in neurological disorders (2021)

Cladribine treatment does not impair humoral response to COVID-19 vaccination. We recommend postponing ocrelizumab treatment in MS patients willing to be vaccinated as a protective humoral response can be expected only in some. We do not recommend vaccinating MS patients treated with fingolimod as a protective humoral response is not expected.

Keyphrases

immune response
multiple sclerosis
coronavirus disease
sars cov
mass spectrometry
newly diagnosed
dendritic cells
ms ms
end stage renal disease
ejection fraction
toll like receptor
combination therapy
binding protein
respiratory syndrome coronavirus